Samira Fafi-Kremer

List of Publications by Year
in descending order

99	12,116	81900 39	38395 95
papers	citations	h-index	g-index

114	114	114	23813
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort. Science Translational Medicine, 2022, 14, eabj7521.	12.4	71
2	Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients. Science Translational Medicine, 2022, 14, eabl6141.	12.4	52
3	A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients. Kidney International, 2022, 101, 1073-1076.	5.2	44
4	Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine. Frontiers in Immunology, 2022, 13, 790212.	4.8	3
5	Combining predictive markers for severe COVID-19: Torquetenovirus DNA load and SARS-CoV-2 RNAemia. Journal of Clinical Virology, 2022, 148, 105120.	3.1	7
6	Humoral immune response after COVID-19 infection or BNT162b2 vaccine among older adults: evolution over time and protective thresholds. GeroScience, 2022, 44, 1229-1240.	4.6	10
7	Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination. Viruses, 2022, 14, 1491.	3.3	13
8	Torque teno virus DNA load as a predictive marker of antibody response to a three-dose regimen of COVID-19 mRNA-based vaccine in lung transplant recipients. Journal of Heart and Lung Transplantation, 2022, 41, 1429-1439.	0.6	13
9	Prediction of Vaccine Response and Development of a Personalized Anti-SARS-CoV-2 Vaccination Strategy in Kidney Transplant Recipients: Results from a Large Single-Center Study. Journal of Personalized Medicine, 2022, 12, 1107.	2.5	5
10	Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019. Clinical Infectious Diseases, 2021, 73, e1762-e1765.	5.8	93
11	Intravenous immunoglobulin as a preventive strategy against BK virus viremia and BKV-associated nephropathy in kidney transplant recipientsâ€"Results from a proof-of-concept study. American Journal of Transplantation, 2021, 21, 329-337.	4.7	24
12	SARS-CoV-2 viral dynamics in immunocompromised patients. American Journal of Transplantation, 2021, 21, 1667-1669.	4.7	23
13	Cerebrospinal Fluid Features in Patients With Coronavirus Disease 2019 and Neurological Manifestations: Correlation with Brain Magnetic Resonance Imaging Findings in 58 Patients. Journal of Infectious Diseases, 2021, 223, 600-609.	4.0	47
14	Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France. Emerging Infectious Diseases, 2021, 27, 113-121.	4.3	176
15	Clinical and Virological Followâ€Up of a Cohort of 76 <scp>COVID</scp>â€19 Older Hospitalized Adults. Journal of the American Geriatrics Society, 2021, 69, 1167-1170.	2.6	4
16	Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study. Lancet Microbe, The, 2021, 2, e60-e69.	7.3	78
17	SARSâ€CoVâ€2 viral load in nasopharyngeal swabs in the emergency department does not predict COVIDâ€19 severity and mortality. Academic Emergency Medicine, 2021, 28, 306-313.	1.8	33
18	Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nature Medicine, 2021, 27, 917-924.	30.7	617

#	Article	IF	Citations
19	Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2. Journal of Infectious Diseases, 2021, 224, 983-988.	4.0	65
20	Long-term shedding of viable SARS-CoV-2 in kidney transplant recipients with COVID-19. American Journal of Transplantation, 2021, 21, 2871-2875.	4.7	33
21	Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine. Kidney International, 2021, 99, 1498-1500.	5.2	163
22	Weak antiâ€“SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. Kidney International, 2021, 99, 1487-1489.	5.2	126
23	Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature, 2021, 596, 276-280.	27.8	1,803
24	Presence of active myocarditis at the 6Âmonth followâ€up appointment for a severe form of COVIDâ€19: a case report. ESC Heart Failure, 2021, 8, 4307-4312.	3.1	8
25	Outbreak of SARS-CoV-2 infection in a long-term care facility after COVID-19 BNT162b2 mRNA vaccination. Clinical Microbiology and Infection, 2021, 27, 1537-1539.	6.0	8
26	Clinical Utility of Biochemical Markers for the Prediction of COVID-19â^'Related Mortality in Kidney Transplant Recipients. Kidney International Reports, 2021, 6, 2689-2693.	0.8	8
27	Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since Infection. Journal of Infectious Diseases, 2021, 224, 1489-1499.	4.0	32
28	Refining â€œLong-COVIDâ€•by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection. Infectious Diseases and Therapy, 2021, 10, 1747-1763.	4.0	55
29	Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19. American Journal of Transplantation, 2021, 21, 3808-3810.	4.7	20
30	High severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroconversion rate among geriatric staff from Strasbourg University Hospitals. Infection Control and Hospital Epidemiology, 2021, , 1-2.	1.8	0
31	Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. EBioMedicine, 2021, 71, 103561.	6.1	172
32	Persistence of SARS-CoV-2 antibodies in kidney transplant recipients. American Journal of Transplantation, 2021, 21, 2307-2310.	4.7	20
33	Biomarkers of Cytokine Release Syndrome Predict Disease Severity and Mortality From COVID-19 in Kidney Transplant Recipients. Transplantation, 2021, 105, 158-169.	1.0	34
34	D-Dimers Level as a Possible Marker of Extravascular Fibrinolysis in COVID-19 Patients. Journal of Clinical Medicine, 2021, 10, 39.	2.4	20
35	COVID-19 exposure in SARS-CoV-2-seropositive hospital staff members during the first pandemic wave at Strasbourg University Hospital, France. Infectious Diseases Now, 2021, , .	1.6	0
36	Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?. Journal of Antimicrobial Chemotherapy, 2020, 75, 183-193.	3.0	8

#	Article	IF	Citations
37	Neurologic and neuroimaging findings in patients with COVID-19. Neurology, 2020, 95, e1868-e1882.	1.1	186
38	Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients. Critical Care, 2020, 24, 491.	5.8	251
39	Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France. EBioMedicine, 2020, 59, 102915.	6.1	101
40	Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies. Diagnostic Microbiology and Infectious Disease, 2020, 98, 115181.	1.8	29
41	In-depth virological assessment of kidney transplant recipients with COVID-19. American Journal of Transplantation, 2020, 20, 3162-3172.	4.7	68
42	Inadequate Immune Humoral Response against JC Virus in Progressive Multifocal Leukoencephalopathy Non-Survivors. Viruses, 2020, 12, 1380.	3.3	4
43	High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Medicine, 2020, 46, 1089-1098.	8.2	2,244
44	Coronavirus disease 2019 in pregnancy was associated with maternal morbidity and preterm birth. American Journal of Obstetrics and Gynecology, 2020, 223, 914.e1-914.e15.	1.3	147
45	Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study. Radiology, 2020, 297, E242-E251.	7.3	333
46	SARS-CoV-2 Pneumonia in Hospitalized Asthmatic Patients Did Not Induce Severe Exacerbation. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2600-2607.	3.8	76
47	First case of COVID-19 in a kidney transplant recipient treated with belatacept. American Journal of Transplantation, 2020, 20, 1944-1946.	4.7	55
48	Neurologic Features in Severe SARS-CoV-2 Infection. New England Journal of Medicine, 2020, 382, 2268-2270.	27.0	2,092
49	Tick-borne encephalitis virus: molecular determinants of neuropathogenesis of an emerging pathogen. Critical Reviews in Microbiology, 2019, 45, 472-493.	6.1	19
50	Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France. Journal of Antimicrobial Chemotherapy, 2019, 74, 1417-1424.	3.0	12
51	Le BK virus en greffe rÃ©nale. Revue Francophone Des Laboratoires, 2019, 2019, 44-52.	0.0	0
52	Letter to the Editor concerning â€œCytomegalovirus prevention strategies and the risk of BK polyomavirus viremia and nephropathyâ€• American Journal of Transplantation, 2019, 19, 3438-3439.	4.7	1
53	Tick-Borne Encephalitis in Auvergne-RhÃ´ne-Alpes Region, France, 2017â€“2018. Emerging Infectious Diseases, 2019, 25, 1944-1948.	4.3	20
54	Intravenous Immunoglobulin Administration Significantly Increases BKPyV Genotype-Specific Neutralizing Antibody Titers in Kidney Transplant Recipients. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	20

#	Article	IF	Citations
55	Torquetenovirus viremia for early prediction of graft rejection after kidney transplantation. Journal of Infection, 2019, 79, 56-60.	3.3	40
56	Clinical utility of leflunomide for BK polyomavirus associated nephropathy in kidney transplant recipients: A multicenter retrospective study. Transplant Infectious Disease, 2019, 21, e13058.	1.7	13
57	Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs. Journal of Antimicrobial Chemotherapy, 2018, 73, 1045-1053.	3.0	9
58	The Authors Reply. Journal of the American Society of Nephrology: JASN, 2018, 29, 1578.2-1578.	6.1	0
59	Neutralizing Antibodyâ€“Mediated Response and Risk of BK Virusâ€“Associated Nephropathy. Journal of the American Society of Nephrology: JASN, 2018, 29, 326-334.	6.1	64
60	A new hot spot for tick-borne encephalitis (TBE): A marked increase of TBE cases in France in 2016. Ticks and Tick-borne Diseases, 2018, 9, 120-125.	2.7	49
61	An unusually high substitution rate in transplant-associated BK polyomavirus in vivo is further concentrated in HLA-C-bound viral peptides. PLoS Pathogens, 2018, 14, e1007368.	4.7	22
62	Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab. Emerging Infectious Diseases, 2018, 24, 1594-1596.	4.3	33
63	Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma. Journal of Antimicrobial Chemotherapy, 2017, 72, 2351-2354.	3.0	7
64	45 years after the discovery of human polyomaviruses BK and JC: Time to speed up the understanding of associated diseases and treatment approaches. Critical Reviews in Microbiology, 2017, 43, 178-195.	6.1	27
65	Microcephaly Caused by Lymphocytic Choriomeningitis Virus. Emerging Infectious Diseases, 2017, 23, 1548-1550.	4.3	26
66	Monoclonal antiâ€envelope antibody AP33 protects humanized mice against a patientâ€derived hepatitis C virus challenge. Hepatology, 2016, 63, 1120-1134.	7.3	30
67	Long-term storage and safe retrieval of human papillomavirus DNA using FTA elute cards. Journal of Virological Methods, 2016, 229, 60-65.	2.1	16
68	Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression. Journal of Antimicrobial Chemotherapy, 2016, 71, 751-761.	3.0	18
69	Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy. Aids, 2015, 29, 1665-1671.	2.2	43
70	HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007â€“12: impact on susceptibility to first-line strategies. Journal of Antimicrobial Chemotherapy, 2015, 70, 2084-2089.	3.0	42
71	Sequence Variation in Amplification Target Genes and Standards Influences Interlaboratory Comparison of BK Virus DNA Load Measurement. Journal of Clinical Microbiology, 2015, 53, 3842-3852.	3.9	27
72	Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma. Journal of Antimicrobial Chemotherapy, 2015, 70, 566-572.	3.0	8

#	Article	IF	Citations
73	Toward Standardization of BK Virus Monitoring: Evaluation of the BK Virus R-gene Kit for Quantification of BK Viral Load in Urine, Whole-Blood, and Plasma Specimens. Journal of Clinical Microbiology, 2014, 52, 4298-4304.	3.9	11
74	Hepatitis C Virus Envelope Glycoprotein Signatures Are Associated With Treatment Failure and Modulation of Viral Entry and Neutralization. Journal of Infectious Diseases, 2013, 207, 1306-1315.	4.0	9
75	Hepatitis C virus vaccines â€“ Progress and perspectives. Microbial Pathogenesis, 2013, 58, 66-72.	2.9	34
76	Neutralizing Antibodies and Pathogenesis of Hepatitis C Virus Infection. Viruses, 2012, 4, 2016-2030.	3.3	23
77	Challenges for HCV vaccine development in HIVâ€“HCV coinfection. Expert Review of Vaccines, 2012, 11, 791-804.	4.4	8
78	Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. Journal of Hepatology, 2012, 57, 17-23.	3.7	72
79	Mutations That Alter Use of Hepatitis C Virus Cell Entry Factors Mediate Escape From Neutralizing Antibodies. Gastroenterology, 2012, 143, 223-233.e9.	1.3	66
80	Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for antiviral therapies. Journal of Hepatology, 2011, 54, 566-576.	3.7	161
81	Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood, 2010, 115, 1145-1155.	1.4	68
82	Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. Journal of Experimental Medicine, 2010, 207, 2019-2031.	8.5	125
83	EBV limbic encephalitis after allogenic hematopoietic stem cell transplantation. Journal of Neuroradiology, 2010, 37, 189-191.	1.1	10
84	Monoclonal Anti-Claudin 1 Antibodies Prevent Hepatitis C Virus Infection of Primary Human Hepatocytes. Gastroenterology, 2010, 139, 953-964.e4.	1.3	151
85	Development of hepatitis C virus vaccines: challenges and progress. Expert Review of Vaccines, 2009, 8, 333-345.	4.4	82
86	Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients. World Journal of Gastroenterology, 2009, 15, 753.	3.3	33
87	Neuroimaging of Epstein-Barr virus infections in children. Pediatric Radiology, 2008, 38, 354-355.	2.0	1
88	Virus-host interactions during hepatitis C virus entry â€" implications for pathogenesis and novel treatment approaches. Virologica Sinica, 2008, 23, 124-131.	3.0	1
89	Evaluation of the Epstein-Barr Virus R-Gene Quantification Kit in Whole Blood with Different Extraction Methods and PCR Platforms. Journal of Molecular Diagnostics, 2008, 10, 78-84.	2.8	25
90	Frequent Compartmentalization of Hepatitis C Virus with Leukocyteâ€Related Amino Acids in the Setting of Liver Transplantation. Journal of Infectious Diseases, 2008, 198, 1656-1666.	4.0	19

#	Article	IF	Citations
91	Proposition dâ€™une nouvelle stratÃ©gie pour Ã©viter la rÃ©infection du greffon par le virus de lâ€™hÃ©patite C aprÃ¨s transplantation hÃ©patique. Bulletin De L'Academie Nationale De Medecine, 2008, 192, 1657-1668.	0.0	0
92	Early Evolution of Hepatitis C Virus (HCV) Quasispecies after Liver Transplant for HCVâ€Related Disease. Journal of Infectious Diseases, 2007, 196, 528-536.	4.0	30
93	Rapid and early virological response to chronic hepatitis C treatment with IFN Â2b or PEG-IFN Â2b plus ribavirin in HIV/HCV co-infected patients. Gut, 2007, 56, 1111-1116.	12.1	46
94	Real-time quantitative PCR for assessment of antiviral drug effects against Epstein-Barr virus replication and EBV late mRNA expression. Journal of Virological Methods, 2007, 143, 38-44.	2.1	18
95	Neutralizing antibodies in hepatitis C virus infection. World Journal of Gastroenterology, 2007, 13, 4824.	3.3	40
96	Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood, 2006, 107, 3053-3057.	1.4	390
97	Longâ€Term Shedding of Infectious Epsteinâ€Barr Virus after Infectious Mononucleosis. Journal of Infectious Diseases, 2005, 191, 985-989.	4.0	108
98	Quantification of gp350/220 Epsteinâ€“Barr Virus (EBV) mRNA by Real-Time Reverse Transcription-PCR in EBV-Associated Diseases. Clinical Chemistry, 2004, 50, 1814-1817.	3.2	6
99	Assessment of automated DNA extraction coupled with real-time PCR for measuring Epsteinâ€“Barr virus load in whole blood, peripheral mononuclear cells and plasma. Journal of Clinical Virology, 2004, 30, 157-164.	3.1	67